The National Cancer Institute now has 70 well-characterized monoclonal antibodies against 26 cancer-specific targets in the Developmental Studies Hybridoma Bank at the University of Iowa, the two parties said this week.
The monoclonal antibodies are the first to be deposited in the DSHB and were developed as part of the NCI's Clinical Proteomic Technologies for Cancer program. The NCI began an initiative to create better characterized and better performing antibodies in late 2007 after hearing from researchers about issues surrounding antibody quality [see PM 11/29/07].
Strategic Diagnostics was awarded the first contract by the NCI as part of the antibody project [see PM 04/10/08] while subsequent requests for proposals have been issued. All antibodies developed as a result of the initiative and their antecedent hybridomas are being deposited in the DSHB, which is making them available to researchers at $25 per milliliter.
In an e-mail to ProteoMonitor, Henry Rodriguez, director of the NCI’s Clinical Proteomic Technologies for Cancer program, said "Now that the system is built and functioning, we are encouraging the research community to tell us targets that require affinity capture reagents [to be] developed against. … This information/input will guide us in the selection of future targets."